# Provectus Biopharmaceuticals, Inc.: overview PVCT · OTC · CIK 315545 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pvct.md) · [Financials](/companies/pvct/financials.md) · [Filings](/companies/pvct/filings.md) · [Insiders](/companies/pvct/insiders.md) Latest reported revenue: [$0](/filings/0001493152-26-012726.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 26, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-012726). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [110](/filings/0001493152-25-022229.md) | [14.3 d](/filings/0001493152-26-012726.md) | [279](/filings/0001493152-26-022950.md) | [57.5](/filings/0001493152-26-037671.md) | [0.0 d](/filings/0001493152-25-022229.md) | [0.0 d](/filings/0001493152-26-012726.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(870.9%)](/filings/0001493152-25-022229.md) | [(16289.0%) d](/filings/0001493152-26-012726.md) | [(394.1%)](/filings/0001493152-26-022950.md) | [(3132.8%)](/filings/0001493152-26-037671.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(924.3%)](/filings/0001493152-25-022229.md) | [(16517.7%) d](/filings/0001493152-26-012726.md) | [(409.2%)](/filings/0001493152-26-022950.md) | [(3156.6%)](/filings/0001493152-26-037671.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.00](/filings/0001493152-25-022229.md) | not reported | [0.00](/filings/0001493152-26-022950.md) | [0.00](/filings/0001493152-26-037671.md) | [0.00](/filings/0001493152-25-022229.md) | not reported | [0.00](/filings/0001493152-26-022950.md) | [0.00](/filings/0001493152-26-037671.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [989](/filings/0001493152-24-011699.md) | [558](/filings/0001641172-25-000993.md) | [617](/filings/0001493152-26-012726.md) | [336](/filings/0001493152-26-012726.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(346.6%)](/filings/0001493152-24-011699.md) | [(520.2%)](/filings/0001641172-25-000993.md) | [(734.4%)](/filings/0001493152-26-012726.md) | [(1575.3%)](/filings/0001493152-26-012726.md) | | Net margin | % | not reported | [(359.4%)](/filings/0001493152-24-011699.md) | [(556.2%)](/filings/0001641172-25-000993.md) | [(766.9%)](/filings/0001493152-26-012726.md) | [(1615.8%)](/filings/0001493152-26-012726.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001493152-22-008016.md) | [(0.01)](/filings/0001493152-24-011699.md) | [(0.01)](/filings/0001641172-25-000993.md) | [(0.01)](/filings/0001493152-26-012726.md) | [(0.01)](/filings/0001493152-26-012726.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pvct/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [HOME FEDERAL BANK OF TENNESSEE](/funds/1665446.md) | 2026-06-30 | $6.9k | 100,000 | | Unchanged | | [Atlas Wealth LLC](/funds/1964106.md) | 2026-06-30 | $1.4k | 19,620 | | Unchanged | | [Financial Symmetry Inc](/funds/2004843.md) | 2026-06-30 | $707 | 10,191 | | Unchanged | | [HUNTINGTON NATIONAL BANK](/funds/49205.md) | 2026-06-30 | $0 | 1 | | Unchanged | ## Recent filings [All 843 filings](/companies/pvct/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 13:21 ET | [10-Q](/filings/0001493152-26-037671.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037671 | | 2026-07-22 | 15:04 ET | [SCHEDULE 13D/A](/filings/0001493152-26-034217.md) | Ownership report, active investor, amended | 0001493152-26-034217 | | 2026-07-01 | 19:37 ET | [8-K](/filings/0001493152-26-031379.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-031379 | | 2026-06-22 | 09:00 ET | [8-K](/filings/0001493152-26-029512.md) | 5.07 Shareholder vote results | 0001493152-26-029512 | | 2026-06-18 | 14:59 ET | [8-K](/filings/0001493152-26-029280.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-029280 | | 2026-05-14 | 13:52 ET | [10-Q](/filings/0001493152-26-022950.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022950 | | 2026-04-30 | 11:06 ET | [DEF 14A](/filings/0001493152-26-019805.md) | Proxy statement, period 2026-04-30 | 0001493152-26-019805 | | 2026-04-21 | 21:19 ET | [8-K](/filings/0001493152-26-018160.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-018160 | | 2026-03-26 | 17:38 ET | [10-K](/filings/0001493152-26-012726.md) | Annual report, period 2025-12-31 | 0001493152-26-012726 | | 2026-02-02 | 15:30 ET | [8-K](/filings/0001493152-26-004730.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-004730 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012726.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 315545 - Tickers: PVCT - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:33 ET. No prices; not investment advice.